Hims Hers Health Inc (HIMS)vsNovartis AG ADR (NVS)
HIMS
Hims Hers Health Inc
$19.39
-7.05%
HEALTHCARE · Cap: $4.86B
NVS
Novartis AG ADR
$149.70
-0.70%
HEALTHCARE · Cap: $286.27B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 2314% more annual revenue ($56.67B vs $2.35B). NVS leads profitability with a 24.7% profit margin vs 5.5%. NVS appears more attractively valued with a PEG of 2.54. NVS earns a higher WallStSmart Score of 51/100 (C-).
HIMS
Hold50
out of 100
Grade: D+
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-538.6%
Fair Value
$3.47
Current Price
$19.39
$15.92 premium
Margin of Safety
-243.7%
Fair Value
$48.62
Current Price
$149.70
$101.08 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 25 in profit
Revenue surging 28.4% year-over-year
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Keeps 25 of every $100 in revenue as profit
Strong operational efficiency at 27.8%
Generating 1.6B in free cash flow
Areas to Watch
Trading at 8.1x book value
Distress zone — elevated risk
5.5% margin — thin
Operating margin of 2.7%
2.2% revenue growth
Grey zone — moderate risk
Expensive relative to growth rate
Earnings declined 11.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : HIMS
The strongest argument for HIMS centers on Return on Equity, Revenue Growth. Revenue growth of 28.4% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 24.7% and operating margin at 27.8%.
Bear Case : HIMS
The primary concerns for HIMS are Price/Book, Altman Z-Score, Profit Margin. A P/E of 41.8x leaves little room for execution misses. Debt-to-equity of 2.34 is elevated, increasing financial risk.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, PEG Ratio.
Key Dynamics to Monitor
HIMS profiles as a growth stock while NVS is a value play — different risk/reward profiles.
HIMS carries more volatility with a beta of 2.61 — expect wider price swings.
HIMS is growing revenue faster at 28.4% — sustainability is the question.
NVS generates stronger free cash flow (1.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 50/100), backed by strong 24.7% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Hims Hers Health Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers with licensed healthcare professionals. The company is headquartered in San Francisco, California.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?